Core Viewpoint - China Medical System Holdings Limited (CMS) announced that its subsidiary Dermavon Holdings Limited has obtained co-development and exclusive commercialization rights for the innovative drug MG-K10, which has received New Drug Application acceptance from the National Medical Products Administration (NMPA) for treating moderate-to-severe atopic dermatitis (AD) [1][3]. Group 1: Product Overview - MG-K10 is a long-acting anti-IL-4Rα humanized monoclonal antibody designed to block IL-4 and IL-13 signaling, allowing for a four-week dosing frequency, which is expected to enhance patient adherence compared to existing biweekly treatments [2][8]. - The product has shown promising results in a Phase III clinical study, with 76.6% of participants achieving an Investigator Global Assessment (IGA) score of 0 or 1, and 94.3% showing a ≥75% reduction in Eczema Area and Severity Index (EASI 75) [3][5]. Group 2: Market Potential - If approved, MG-K10 could serve as a new treatment option for approximately 14.5 million patients with moderate-to-severe AD in China, addressing significant unmet medical needs in this patient population [5][7]. - The product also has potential applications for other type 2 inflammatory diseases, with ongoing Phase III trials for asthma, prurigo nodularis, and seasonal allergic rhinitis in China [4][5]. Group 3: Strategic Partnerships - CMS has entered into a Collaboration Agreement with Hunan Mabgeek Biotech Co., LTD for MG-K10, securing rights for co-development and commercialization in various regions including Mainland China and Hong Kong [6][9]. Group 4: Company Background - CMS focuses on innovative pharmaceutical products, particularly first-in-class and best-in-class therapies, and has established a strong presence in specialty therapeutic fields, including skin health through its subsidiary Dermavon [9][10][11].

GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it will report its third quarter 2025 financial results on Thursday, November 6, 2025. Altimmune management will host a conference call at 8:30 a.m. ET on November 6 to discuss financial results and provide a business update. The conference call will be webcast live on Altim ...

Not for distribution to United States Newswire Services or for dissemination in the United States TORONTO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sparton Resources Inc. (TSXV-SRI) (“Sparton” or the “Company”) is pleased to announce non-brokered private placements (the “Offering”) for gross proceeds of up to C$500,000. The Offering will be in Units and will consist of a combination of Quebec Flow Through Shares (“QFTS”), Federal Flow Through Share (“FFTS”), (collectively called “FTS”), Non-Flow Through Share (“NF ...

Core Insights - Profusa, Inc. is set to commercialize its Lumee tissue oxygen monitoring technology in the European Union by early Q2 2026, with plans for U.S. market entry and expanded indications to follow [1][4][6] Revenue Projections - The company anticipates potential revenue of $200 to $250 million by 2030, driven by its Lumee technology and additional indications such as continuous glucose monitoring [2][5] - In 2026, Profusa projects revenue of $0.5 to $2 million from tissue oxygen monitoring in Europe, with a target of $9 to $13 million in 2027 [6][7] Market Potential - The global addressable market for tissue oxygen monitoring is estimated at $10.5 billion, particularly in conditions like peripheral artery disease and critical limb ischemia, with over 716,000 CLI procedures performed annually in Europe [5] - The continuous glucose monitoring market is expected to expand significantly, targeting over 500 million individuals with type 1, type 2, or pre-diabetes worldwide [5] Technological Advancements - Profusa's Lumee technology allows for continuous, real-time measurement of tissue oxygen, providing a less invasive and more convenient experience for patients, while also reducing healthcare costs through improved disease management [3][4] Strategic Partnerships and Distribution - Profusa has established manufacturing capabilities and distributor partnerships, covering approximately 35% of the European population through its intended distribution channels [2][6] - The company plans to layer additional indications onto its Lumee platform over time, including lactate, carbon dioxide, sodium, and ethanol [7]

- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors - Selective CBP degrader is on track for non-GLP toxicology studies in Q4 2025 with potential in EP300-mutant cancers and in ER+ breast cancer; IND-ready in 2026 - Selective EP300 degrader demonstrates efficacy and favorable tolerability in preclinical models in hematological malignancies with significant differ ...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025 MIAMI, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“Digi Power X” or the “Company”) (Nasdaq: DGXX / TSXV: DGX), a U.S. developer of Tier III-grade high-performance computing (HPC) infrastructure, plans to announce its financial results for the quarter ended September 30, 2025(all amounts in U.S. dollars, unles ...

Core Viewpoint - First National Corporation reported a record financial performance for the third quarter of 2025, with earnings of $5.55 million and earnings per share of $0.62, reflecting an increase from both the previous quarter and the same period last year [1][2]. Financial Highlights - Earnings per share increased by 11% from the previous quarter and 72% year-over-year [5]. - Return on average assets improved to 1.09% from 1.00% in the previous quarter and 0.62% a year ago [5]. - Return on average equity rose to 12.43% compared to 11.85% in the previous quarter and 7.28% one year prior [5]. - Net interest margin (FTE) was 3.84%, up from 3.43% a year earlier [5]. - Net loans held for investment reached $1.419 billion, a 44.5% increase from the previous year [5]. - Total deposits amounted to $1.810 billion, up 44.4% year-over-year [5]. Net Interest Income - Net interest income for the third quarter was $18.3 million, a decrease of $253 thousand from the previous quarter [4]. - The net interest margin decreased to 3.84% from 3.95% in the second quarter of 2025 [4]. - Earning asset yields decreased by 9 basis points to 5.26% compared to the previous quarter [4]. Allowance and Provision for Credit Losses - The provision for credit losses was $193 thousand, significantly lower than the $911 thousand recorded in the previous quarter [5]. - The allowance for credit losses on loans totaled $14.4 million, or 1.01% of total loans [7]. Noninterest Income and Expense - Noninterest income increased by $611 thousand to $4.5 million, primarily due to higher ATM and check card income [8]. - Noninterest expense rose to $15.8 million, driven by increases in salaries and employee benefits [10]. Balance Sheet - Total assets were $2.031 billion, a slight decrease from the previous quarter but a 40% increase from the previous year [12]. - Total debt security investments increased to $305.5 million, up 2.0% from the previous quarter [14]. - Total deposits increased by $6.4 million from the prior quarter, primarily due to interest-bearing demand deposits [15]. Asset Quality - Non-performing assets (NPAs) improved to 0.28% of total assets, down from 0.33% in the previous quarter [19]. - Loans past due over 90 days increased to $388 thousand, while loans past due 30-89 days rose to $3.6 million [20]. Capital - Tangible book value per share grew to $18.26, up from $17.40 in the previous quarter [21]. - The total risk-based capital ratio was 15.15%, an increase from 14.89% in the previous quarter [22].

Core Insights - DT Midstream, Inc. reported a net income of $115 million for Q3 2025, equating to $1.13 per diluted share, with Operating Earnings also at $115 million and Adjusted EBITDA at $288 million [1][2][18] Financial Performance - The company declared a dividend of $0.82 per share, payable on January 15, 2026, to stockholders of record by December 15, 2025 [2] - Year-to-date results are ahead of plan, prompting an increase in Adjusted EBITDA guidance for 2025 to a range of $1,115 million to $1,145 million [2][9] Business Updates - Significant progress was made in both commercial and construction activities during the quarter [2] - The company reached a final investment decision on the Guardian Pipeline "G3" expansion, increasing pipeline capacity by approximately 537 million cubic feet per day (MMcf/d), a 40% increase [6] - The LEAP Phase 4 expansion project was placed in-service ahead of schedule and on budget [6] Company Overview - DT Midstream operates natural gas interstate and intrastate pipelines, storage, and gathering systems, serving utilities, power plants, and large industrial customers across the U.S. and Canada [3] - The company aims to achieve net zero greenhouse gas emissions by 2050, with a target of 30% carbon emissions reduction by 2030 [3] Financial Metrics - Adjusted EBITDA is defined as GAAP net income before interest, taxes, depreciation, and amortization, adjusted for non-routine items [5][8] - Distributable Cash Flow (DCF) is calculated by adjusting net income for various expenses and is considered a key measure of the company's ability to generate cash earnings [8][22]

MIAMI, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Laureate Education, Inc. (NASDAQ: LAUR), which operates five higher education institutions across Mexico and Peru, today announced financial results for the third quarter and nine months ended September 30, 2025. Third Quarter 2025 Highlights (compared to third quarter 2024): On a reported basis, revenue increased 9% to $400.2 million. On an organic constant currency basis1, revenue increased 4% and was unfavorably affected by approximately $7 million of intra-year a ...

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Dynacor Group Inc. (TSX: DNG) (“Dynacor” or the "Corporation") is pleased to provide an update on its expansion plan within West Africa and Latin America. The Corporation’s expansion is expected to generate more than US$1 billion in sales by 2030, a more than 250% increase on 2024 sales. Recent Progress Senegal – Construction of the 50-tpd pilot plant in Senegal continues on schedule. The first shipments of the modular plant have left Durban and are expected on si ...